ScreenerHero

GLSI Greenwich LifeSciences, Inc.

NAS · US · Healthcare · Biotechnology · greenwichlifesciences.com
15.14USD-1.62%Mkt Cap: 222.23M $P/E: —

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap222.23M USD
Enterprise Value222.89M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.36M USD
Revenue/Share—
Last Price15.14 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-19.26
PEG—
EV/EBITDA-9.84
EV/Revenue—
P/S—
P/B74.48
EPS (TTM)-1.43
EPS (Forward)-0.82
52W Range
7.78028% of range34.10
52W High34.10 USD
52W Low7.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-5480.55%
ROA-313.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.91M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.50%
Net Debt-8.88M USD
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity—
Current Ratio1.54
Quick Ratio1.54
Book Value/Sh0.21 USD
Cash/Share0.60 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)57.00 USD
Upside (mean)+276.5%
Target Range45.00 USD – 69.00 USD
45.00+276.5% to mean69.00
# Analysts2
Ownership
Shares Out.14.68M
Float7.65M
Insiders47.91%
Institutions12.25%
Short Interest
Short Ratio14.0d
Short % Float21.31%
Short % Out.11.11%
Shares Short1.63M
Short (prev mo.)1.59M
Technical
SMA 5016.28 (-7.0%)
SMA 20021.93 (-31.0%)
Beta1.46
S&P 52W Chg16.45%
Avg Vol (30d)122.12K
Avg Vol (10d)115.39K
Technical Indicators
RSI (14)39.5
MACD-0.1403
MACD Signal0.2021
MACD Hist.-0.3424
BB Upper19.98 USD
BB Middle17.06 USD
BB Lower14.14 USD
BB Width34.24%
ATR (14)1.417 USD
Vol Ratio (20d)1.10x